Drug Approval | March 09, 2023
Eugia Pharma receives USFDA approval for Lenalidomide Capsules
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Lenalidomide is used to treat various types of cancers.
Celgene agreed to provide Dr. Reddy's with a license to sell volume-limited amounts of generic lenalidomide capsules in the U.S.
ICICI Direct’s analysis of Cipla’s Q3FY22 results
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
_256_384.jpg)
In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Subscribe To Our Newsletter & Stay Updated
